Quarterly report [Sections 13 or 15(d)]

Statements of Cash Flows

v3.26.1
Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash Flows from Operating Activities:    
Net loss $ (955) $ (153)
Adjustments to reconcile net loss to net cash used in operating activities:    
Issuance of common shares - equity fee on equity offerings to Fortress Biotech 0 216
Stock-based compensation expenses 22 38
Depreciation expense 0 34
Amortization of operating lease right-of-use assets 0 7
Settlement of payables (76) (701)
Gain on lease termination 0 (394)
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 3 (11)
Other receivables 0 185
Accounts payable and accrued expenses (20) (683)
Payable and accrued expenses - related party 18 146
Lease liabilities 0 (73)
Net cash used in operating activities (1,008) (1,389)
Cash Flows from Investing Activities:    
Proceeds from the sale of property and equipment 0 1,165
Net cash from investing activities 0 1,165
Cash Flows from Financing Activities:    
Proceeds from issuance of common shares, net of offering costs - equity offering 0 7,017
Proceeds from issuance of common shares, net of offering costs - At-the-Market offering 0 599
Net cash provided by financing activities 0 7,616
Net change in cash and cash equivalents (1,008) 7,392
Cash and cash equivalents, beginning of the period 17,266 6,839
Cash and cash equivalents, end of the period 16,258 14,231
Supplemental disclosure of noncash activities:    
Issuance of common shares - Founders Agreement and equity fee to Fortress 273 611
Unpaid offering costs - equity offering $ 0 $ 235